Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Wyeth ReFacto Launch Set For Third Quarter; Awaiting Adequate Supply

  • News

Executive Summary

Wyeth-Ayerst is awaiting the production of commercial quantities of its antihemophilic factor ReFacto for introduction into the U.S. market.

You may also be interested in...



Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason

Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product

Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason

Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product

Wyeth To File Refacto AF Second Quarter; Will Launch End Supply Problems?

Wyeth plans to file its second-generation antihemophilic factor VIII product Refacto AF during the second quarter, Wyeth President-Global Pharmaceuticals Bernard Poussot said during a Jan. 28 analyst call

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS035745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By